Bristol Myers Squibb (NYSE: BMY) today announced that the Phase 3 CheckMate -816 trial met a primary endpoint of pathologic complete response (pCR) in resectable non-small cell lung cancer (NSCLC). In the trial, significantly more patients treated with Opdivo (nivolumab) plus chemotherapy before surgery showed no evidence of cancer cells […]
Metal Cutting Tools Market will Showcase Neutral Impact during 2020-2024|Growth In Automotive Industry to Boost the Market Growth
2 years ago